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In vitro human studies show that the metabolism of most amphetamine-like
psychostimulants is regulated by the polymorphic cytochrome P450 isozyme CYP2D6.
Two compounds, methamphetamine and 3,4-methylenedioxymethamphetamine
(MDMA), were selected as archetypes to discuss the translation and clinical significance
of in vitro to in vivo findings. Both compounds were chosen based on their differential
interaction with CYP2D6 and their high abuse prevalence in society. Methamphetamine
behaves as both a weak substrate and competitive inhibitor of CYP2D6, while MDMA
acts as a high affinity substrate and potent mechanism-based inhibitor (MBI) of the
enzyme. The MBI behavior of MDMA on CYP2D6 implies that subjects, irrespective of
their genotype/phenotype, are phenocopied to the poor metabolizer (PM) phenotype.
The fraction of metabolic clearance regulated by CYP2D6 for both drugs is substantially
lower than expected from in vitro studies. Other isoenzymes of cytochrome P450 and
a relevant contribution of renal excretion play a part in their clearance. These facts tune
down the potential contribution of CYP2D6 polymorphism in the clinical outcomes of both
substances. Globally, the clinical relevance of CYP2D6 polymorphism is lower than that
predicted by in vitro studies.
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INTRODUCTION
Amphetamine-type stimulants (ATS) make up a group of
substances comprised of synthetic stimulants including
amphetamine, methamphetamine, methcathinone, and ecstasy-
group substances [e.g., 3,4-methylenedioxymethamphetamine
(MDMA) and its analogues]. According to the latest report pub-
lished by UNODC, ATS such as “ecstasy” and methamphetamine
now rank as the world’s second most widely abused drug type
after cannabis (UNODC, 2011).
In vitro human studies show that the metabolism of most
psychostimulants belonging to this class of compounds is reg-
ulated by the polymorphic cytochrome P450 isozyme CYP2D6.
In addition, some of them behave both as substrates and
inhibitors of CYPD6 and several other CYP isozymes (Wu
et al., 1997; see Table 1). The gene (CYP2D6) environment
(drug use, gender, ethnicity. . . ) interaction has been evalu-
ated in drug users in order to evaluate: (1) intensity of drug
effects, (2) susceptibility to acute toxicity episodes and fatali-
ties, (3) susceptibility to drug dependence, (4) contribution to
drug induced neurotoxicity, and (5) drug-drug pharmacological
interactions.
The fact that this polymorphic enzyme partially regulates
metabolic disposition leads us to postulate that acute toxicity,
drug abuse and dependence as well as, in some cases, long-term
neurotoxicity could be influenced by CYP2D6 genetics (Sellers
and Tyndale, 2000; de la Torre and Farré, 2004; Perfetti et al.,
2009). Specifically, it was postulated that:
1. Subjects carrying genotypes which lead to enzymatic func-
tional phenotypes should display an increased risk of drug
abuse proportionate to their genotype (homozygous vs. het-
erozygous) and absolute level of enzyme activity.
2. Subjects carrying genotypes which lead to enzymatic func-
tional phenotypes should display an increased risk of neuro-
toxicity proportionate to their genotype and absolute level of
enzyme activity if the underlying mechanism is unrelated to a
metabolic bioactivation.
3. Subjects carrying genotypes which lead to non-functional
enzyme should experience greater risk of toxicity to a drug
which is not metabolically inactivated, and might be less likely
to acquire drug-taking behavior.
The present review will examine available clinical data to deter-
mine to what extent these postulates have been confirmed. Due to
the fact that ATS are a broad class of compounds encompassing
a number of substances, and that scant in vivo data from human
studies are available for most of them (Wu et al., 1997), the review
will focus mainly on the following two: MDMA (ecstasy) and
methamphetamine. They will serve as archetypes in order to dis-
cuss the translation and clinical significance of in vitro to in vivo
findings. Both compounds were chosen based on their differential
interaction with CYP2D6 and their abuse prevalence in society.
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CYP2D6, MDMA, AND METHAMPHETAMINE: BACKGROUND
CONSIDERATIONS
CYP2D6 accounts for only a small percentage of total hep-
atic cytochrome P450 (1–2%), yet it is responsible for the
metabolism of approximately 20–30% of marketed pharma-
ceuticals, including tricyclic antidepressants, selective serotonin
reuptake inhibitor antidepressants, opioids, and antipsychotic,
antiemetic, antiarrhythmic, and amphetamine-like drugs
(Ingelman-Sundberg, 2005). CYP2D6 exhibits a marked genetic
polymorphism—over 70 alleles (www.cypalleles.ki.se/cyp2d6.
htm) have been described whose combination leads to four
phenotypes: poor, intermediate, extensive, and ultrarapid metab-
olizers (PM, IM, EM, and UM, respectively). Subjects with a
PM phenotype lack two functional alleles; those with an IM
have one reduced-activity allele and one non-functional allele or
two reduced-activity alleles; whereas EM individuals have one
or two functional alleles; and the UM phenotype is associated
with gene duplications of functional alleles, with an increased
protein expression (Zanger et al., 2004; Bogni et al., 2005). About
5–10% of Caucasians are PM, presenting a metabolic deficiency
in CYP2D6 activity (Sachse et al., 1997).
CYP2D6 regulates MDMA O-demethylenation leading to
the formation of 3,4-dihydroxymethamphetamine (HHMA)
and the 4-hydroxylation of methamphetamine (pholedrine)
(see and Figures 1 2). Both compounds are, therefore, sub-
strates of the same enzyme although the rates by which
they are oxidized differ markedly. MDMA oxidation takes
place at almost 100 times the rate of methamphetamine
oxidation (see Table 1) (Lin et al., 1997). While metham-
phetamine is both a substrate and competitive inhibitor of
CYP2D6, MDMA acts as a substrate and potent mechanism-
based inhibitor (MBI) of the enzyme (Delaforge et al.,
1999).
The east and south–east regions of Asia home to about
one-third of the global population, have one of the most
strongly established markets for ATS in the world, primarily for
methamphetamine (UNODC, 2011). This is of relevance since
the CYP2D6*10 allelic variant, which encodes a hypofunctional
enzyme, is carried by approximately 75% of the Asian popula-
tion. An in vitro study comparing catalytically the CYP2D6*10
allelic variant vs. CYP2D6*1 (wild type), which is more preva-
lent in Caucasians, showed that the ratios of intrinsic clearance
(Vmax/Km) of *1 to *10 for MDMAO-demethylenation was 123,
and for methamphetamine 67, for the p-hydroxylation 157 of
the N-demethylation (Ramamoorthy et al., 2001). This almost
100-fold difference in intrinsic clearance for both drugs, depend-
ing on the allelic variant considered, is of significance in the
interpretation of clinical data. Findings observed in Caucasian
populations with respect to the impact ofCYP2D6 polymorphism
on drug effects are not always reproduced in Asian ones. This lack
of reproducibility is due to the distribution of extreme pheno-
types (UM and PM) in these populations. Globally, however, the
rate of metabolic disposition of CYP2D6 substrates is slower in
Asians.
Another aspect to be considered is the common belief that
amongst drug abuser populations genotypes are distributed
according to the same patterns as the general population. In
the case of CYP2D6, assuming that PM subjects have a higher
tendency to accumulate drug in the body, either these sub-
jects discontinue drug consumption or autoregulate it by taking
lower doses. Due to the relatively small size of the populations
evaluated in clinical studies (in terms of guaranteeing a fair rep-
resentation of all genotypes), the number of subjects carrying
extreme genotypes is usually quite small. In fact, the authors
of the present review believe that PM subjects are underrepre-
sented in MDMA and other amphetamine-like compound user
FIGURE 1 | Simplified scheme of MDMA main metabolic
pathways. For a more detailed description, readers are referred to de la
Torre et al. (2004). MDMA (3,4-methylendioxymethampetamine), MDA
(3,4-methylendioxyampetamine), HHMA (3,4-dihydroxy methamphetamine),
HMMA (3-methoxy-4-hydroxymethamphetamine), HHA
(3,4-dihydroxyamphetamine), and HMA (3-methoxy-4-hydroxyamphetamine).
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FIGURE 2 | Simplified scheme of methamphetaminemain metabolic pathways. For a more detailed description, readers are referred to Shima et al. (2006).
populations probably because of the acute effects experienced.
This bias has to be taken into consideration when interpreting
clinical data.
MDMA PHARMACOLOGY AND METABOLIC DISPOSITION
MDMA is a psychostimulant drug that displays effects related
to amphetamine-type drugs plus a number of distinctive ones
(closeness to others, facilitation to interpersonal relationship,
and empathy) that have been named by some authors as entac-
togen properties. MDMA is a potent releaser and/or reuptake
inhibitor of presynaptic serotonin (5-HT), dopamine (DA), and
norepinephrine (NE). These actions result from the interaction
of MDMA with the membrane transporters involved in neuro-
transmitter reuptake and vesicular storage systems. MDMA is a
mild inhibitor of monoamine oxidase (MAO) and also has direct
action on several types of receptors including the 5-HT2 receptor,
the M1 muscarinic receptor, the α2-adrenergic receptor, and the
histamine H1 receptor.
The most frequent effects after MDMA administration are
euphoria, well-being, happiness, stimulation, increased energy,
extroversion, feeling close to others, increased empathy, increased
sociability, enhanced mood, and mild perceptual disturbances.
In addition, cardiovascular related somatic symptoms, auto-
nomic effects (dry mouth, sweating, tremor, mydriasis tremor,
jaw clenching, and restlessness), and moderate derealization have
been observed (de la Torre et al., 2004).
MDMA induced acute toxic effects are related to its pharma-
cologic actions. Hyponatremia is an uncommon complication
associated with inappropriate antidiuretic hormone (SIADH)
secretion and excessive water intake. Fulminant hepatitis and hep-
atic necrosis have been described (Henry et al., 1992; de la Torre
et al., 2004). Chronic use of MDMA is linked to a progressive
neurodegeneration of the serotonergic neurotransmission system
(Green et al., 2003).
Two main pathways are involved in MDMA metabolic
clearance: (1) O-demethylenation partially regulated
by CYP2D6 followed by catechol-O-methyltransferase
(COMT)-catalyzed methylation (HMMA) and/or glucuronide/
sulfate conjugation; and (2) N-dealkylation leading to 3,4-
methylenedioxyamphetanmine (MDA), further subject to
similar metabolic reactions as MDMA (O-demethylenation and
O-methylation) (see Figure 1). MDMA metabolic clearance
accounts for about 75% of plasma clearance and 30% of its
metabolism is regulated by CYP2D6 (de la Torre et al., 2000;
Segura et al., 2005).
MDMA CYP2D6 MECHANISM-BASED INHIBITION AND THE
PHENOCOPYING PHENOMENON
As previously stated, whilst MDMA is metabolized by CYP2D6
it is also a potent MBI of the enzyme (de la Torre et al., 2000;
Farré et al., 2004; Heydari et al., 2004; Yang et al., 2006). MBI
occurs shortly after a single recreational dose, inactivating most
hepatic CYP2D6 within 2 h, and returning to a basal level of
CYP2D6 activity after at least 10 days (O’Mathúna et al., 2008;
Yubero-Lahoz et al., 2011). This phenomenon is associated with
a decrease in the amount of effective enzyme so that recovery of
activity depends on its de novo synthesis (Liston et al., 2002). In
MBI there is a rapid phenocopying to apparent PM status after
a single dose of MDMA, which signifies that within 2 h sub-
jects display the PM phenotype after drug intake, irrespective of
their original genotype. Previous clinical trials have reported that
the phenocopying phenomenon was observed in 67% of male
subjects (O’Mathúna et al., 2008) and in 100% of the females
(Yubero-Lahoz et al., 2011). Therefore, recreational MDMA users
(including those who take repeated doses in the same session)
are exposed to a higher probability of relative overdose and an
increased risk of suffering adverse effects fromCYP2D6 substrates
(Farré et al., 2004).
MDMA AND CYP2D6 PHARMACOGENETICS
Most research evaluating the potential impact of CYP2D6 phar-
macogenetics in MDMA pharmacology has been focused on
acute effects. Preliminary in vitro studies showing that MDMA
was a CYP2D6 substrate raised the possibility that subject carriers
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Table 1 | Interaction of amphetamine-like and related
psychostimulants with CYP2D6: affinity and inhibitory capacity.
Amphetamine derivatives Ki (µM)a Km (µM)
±3,4-Methylenedioxymethamphetamine
(MDMA)
0.6±0.6 2.2±1.6b
±3,4-Methylenedioxyamphetamine (MDA) 1.8±1.0 11.6±5.4b
±-3,4-methylenedioxyethylamphetamine
(MDE)
2.6±1.4b
+Amphetamine 26.5±1.5
+Methamphetamine 25.0 39.6±4.7c
±-2-Methoxyamphetamine 11.5±0.5
±-3-Methoxyamphetamine 17.5±2.5
±-4-Methoxyamphetamine (PMA) 24±6 29.3±4.4d
±-4-Hydroxyamphetamine 195±45
±-4-Hydroxymethamphetamine 60±10
p-Methoxymethamphetamine (PMMA) 4.6±1.0e
4-methoxy-Nethylamphetamine (M-NEA) 19.5±1.4d
N-butylamphetamine (NBA) 3.7±0.3d
4-methoxy-N-butylamphetamine (M-NBA) 11.9±1.8d
±-2,4,6-Trimethoxyamphetamine
(2,4,6-TMA)
33±12
±-3,4,5-Trimethoxyampthetamine
(3,4,5-TMA)
128±3
benzodioxolyl-butanamine (BDB) 0.8±0.1f
N-methyl-benzodioxolyl-butanamine (MBDB) 1.0±0.02g
4′-Methyl-α-pyrrolidinopropiophenone
(MPPP)
9.8±2.5h
4′-methoxy-α -pyrrolidinopropiophenone
(MOPPP)
9.9±2.5i
3′,4′-methylenedioxy-α-
pyrrolidinopropiophenone
(MDPPP)
13.5±1.5j
a (Wu et al., 1997).
b(Kreth et al., 2000).
c (Lin et al., 1997).
d (Bach et al., 1999).
e(Staack et al., 2004). Calculated as pmol/min/pmol P450.
f (Meyer et al., 2009b). Calculated as pooled human liver microsomes
(pHLM 20 mg microsomal protein/mL, 400 pmol total P450/mg protein).
g (Meyer et al., 2009a). Calculated as pooled human liver microsomes
(pHLM 20 mg microsomal protein/mL, 400 pmol total P450/mg protein).
h(Springer et al., 2003a). Calculated as pmol/min/pmol P450.
i (Springer et al., 2003b). Calculated as pmol/min/pmol P450.
j (Springer et al., 2003c). Calculated as pmol/min/pmol P450.
of allelic variants leading to the PMphenotype for CYP2D6might
be at increased risk of acute toxicity episodes and higher abuse lia-
bility (Tucker et al., 1994; Henry and Hill, 1998; de la Torre et al.,
1999). Conversely, since long-term neurotoxicity is believed to
be mediated by metabolites formed after methylenedioxyphenyl
ring-opening by CYP2D6 (de la Torre and Farré, 2004; Jones et al.,
2005), PM might be protected against chronic toxicity (Perfetti
et al., 2009). However, toxicological data do not seem to fully
support these expectations since in a series of acute intoxications,
high plasmaMDMA concentrations have been reported although
an overrepresentation of genotypes (homozygous for the *3 and
*4 allelic variants examined) leading to the PM phenotype was
not found (O’Donohoe et al., 1998; Schwab et al., 1999; Gilhooly
and Daly, 2002). Unfortunately, few data are available concern-
ing the clinical pharmacology of MDMA in PM individuals. A
previous study reported that PM (homozygous *4/*4) subjects
display increased plasma concentrations, and an increased risk of
hyperthermia, after a single dose of MDMA. A similar observa-
tion has been reported for another methylenedioxyamphetamine
derivative,3,4-methylenedioxyethylamphetamine (MDE) (Kreth
et al., 2000). Concerning MDMA, due to CYP2D6 autoinhibi-
tion and, therefore, the phenomenon of phenocopying towards
the PM phenotype, effects experienced by EM subjects (*1/*1,
n = 6, and *1/*4 n = 3) after two consecutive doses of the drug
(Farré et al., 2004; de la Torre et al., 2005) are similar to those
of PM ones (*4/*4). Other studies have reported that drug
side effects are related individuals with low-activity of CYP2D6
(EM/IM category, comprising the following genotypes: *2/*9,
*1/*10, *1/*41, *2/*41, *2/*35, *35/*35, and *35/*41) display-
ing an increased induction of plasma hypo-osmolality, hypona-
tremia, and increased plasma antidiuretic hormone (vasopressin)
after MDMA consumption (Aitchison et al., 2012). Moreover,
the PM/IM (*4/*29, *5/*41, and *6/*41) or the IM/IM (*41/*41)
genotypes were related to a greater degree of increase in plasma
cortisol concentration than the other CYP2D6 after MDMA
intake (Wolff et al., 2012).
The formation of tioether adducts with quinones resulting
from the auto-oxidation of the MDMA catechol type metabo-
lites HHMA and HHA (3,4-dihydroxyamphetamine) is one of
the hypotheses for MDMA induced neurotoxicity. These com-
pounds can easily enter into redox cycling, generating radical
oxygen species, which are the underlying mechanism of MDMA
neurotoxicity. Genetic polymorphisms in CYP2D6 and catechol-
O-methyltransferase, the combination of which are major deter-
minants of steady-state levels of HHMA and HMMA, probably
explain the interindividual variability seen in the recovery of
N-acetyl-cysteinyl adducts from urine (N-Ac-5-Cys-HHMA and
N-Ac-5-Cys-HHA). The recovery was marginally related to the
CYP2D6 genotype among EM subjects (one vs. two functional
alleles) (p < 0.1) and to the COMT val158met genotype (p <
0.1) of subjects. The recovery of N-Ac-5-Cys-HHMA was 2-fold
higher among met/met subjects compared with the value for the
val/val subjects (Perfetti et al., 2009).
MDMA DRUG–DRUG INTERACTIONS
MDMA, once taken, is not selective to CYP2D6 and interacts with
several isozymes of P450. In fact, the contribution of CYP2D6
to MDMA metabolism has been reported to be less than 30%
(Segura et al., 2005). Thus, several other P450 isoenzymes such
as CYP1A2 and, to a lesser extent, CYP2B6 and CYP3A4 have the
capacity to contribute to the microsomal oxidative metabolism
of MDMA and MDA A recent study showed that while CYP2D6
was inhibited by MDMA, CYP1A2 increased its activity (Yubero-
Lahoz et al., 2012). Another clinical trial showed there was a
conversion from MDMA to HHMA in vivo, despite the CYP2D6
inhibition by paroxetine, suggesting alternative metabolic path-
ways (Segura et al., 2005). Other enzymes may, therefore, become
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more predominant once CYP2D6 is inhibitedwhich could further
contribute to MDMA metabolic disposition.
The administration of inhibitors of CYP2D6 activity can
influence the metabolism of MDMA, and in turn MDMA
can inhibit drugs metabolized by CYP2D6. Previous admin-
istration of antidepressants with CYP2D6 inhibitory actions,
such as paroxetine, reboxetine, or duloxetine, produce 15–30%
of MDMA concentrations, but decrease concentrations of its
metabolite HMMA by 40–50% (Segura et al., 2005; Farré et al.,
2007; Hysek et al., 2011, 2012). Moreover, the pharmacological
effects of MDMA are decreased, probably due to competition for
the uptake transporter decreasing MDMA entry in neurons.
CYP2D6 is also the source of a number of drug–amphetamine
interactions because it regulates the biotransformation of many
therapeutic drugs. Antiretroviral drugs (ritonavir, a known
CYP2D6 inhibitor) and MAO inhibitors have been reported to
be the main cause of life threatening interactions with MDMA
(Henry and Hill, 1998; de la Torre et al., 1999; Papaseit et al.,
2012).
METHAMPHETAMINE PHARMACOLOGY AND METABOLIC
DISPOSITION
Methamphetamine is an indirect sympathomimetic agent, similar
in structure to amphetamine. Nevertheless, an added N-methyl
group confers increased lipid solubility, allowing for more rapid
diffusion into the central nervous system. Methamphetamine
effects derive from their interaction with a number of neurotrans-
mitter systems; primarily with the dopaminergic but also with
serotonergic, noradrenergic, and glutamatergic systems. Acute
adverse effects including cardiovascular and psychoactive ones are
related to an excess of neurotransmitters. As previously explained,
long-term methamphetamine induced effects are the result of
a neurodegeneration of the dopaminergic system (Schep et al.,
2010).
There are three main biotransformation pathways (see
Figure 2) involved in methamphetamine metabolic clearance: (1)
N-demethylation to produce amphetamine, (2) aromatic hydrox-
ylation producing 4-hydroxymethamphetamine (pholedrine)
with both reactions partially regulated by CYP2D6 (Lin et al.,
1997), and (3) beta-hydroxylation to produce norephedrine.
Metabolic clearance represents more than 50% of total plasma
clearance (Cook et al., 1993).
METHAMPHETAMINE AND CYP2D6 PHARMACOGENETICS
A review of the current literature for genetic-association stud-
ies of methamphetamine use disorders, including 38 studies and
39 genes, showed that 18 genes were found to have a signif-
icant genotypic, allelic, and/or haplotypic association. Among
these genes was CYP2D6 which was associated with metham-
phetamine dependence (Bousman et al., 2009). Of particular
relevance was a report in which a total of 202 patients with
methamphetamine dependence and 337 controls in a Japanese
population were genotyped for CYP2D6*1, *4, *5, *10, and *14.
A significant association of the CYP2D6 genotype with metham-
phetamine dependence (p = 0.03) was reported. There were
fewer patients carrying the hypofunctional alleles *10 and *14
alleles than in the control population, and in this population
there were no PMs. IMs of CYP2D6 were significantly fewer
among methamphetamine-dependent subjects than in controls
(p = 0.02), with an odds ratio of 0.62 (95% confidence inter-
val: 0.51–0.76). A potential conclusion of this study is that a
lower CYP2D6 activity seems to confer some degree of protection
against methamphetamine dependence (Otani et al., 2008).
In a study performed in Caucasians it was observed that EM
(n = 8) and PM (n = 3) subjects administered with metham-
phetamine by the oral route (10 mg) displayed a similar area
under the curve for plasma methamphetamine concentrations,
despite the fact that p-hydroxymethamphetamine was only
observed in PM subjects. PM subjects appeared to be more sen-
sitive to the slope of plasma methamphetamine concentrations in
several measurements of subjective effects. The data suggest that
brainmethamphetamine concentrations (in the absence of differ-
ences in plasma concentrations) are higher in PM subjects or that
they have a steeper concentration-response relationship (Sellers
and Tyndale, 2000).
Methamphetamine use may induce the following physical
effects: anorexia, hyperactivity, dilated pupils, flushing, restless-
ness, dry mouth, bruxism, headache, cardiovascular alterations
in heart rate, and blood pressure. It may cause rhabdomyoly-
sis which has been associated with mortality. In a series of 18
autopsies genetic susceptibility to rhabdomyolysis was examined.
Mutations of the following genes were studied: ryanodine recep-
tor 1 (RYR 1), carnitine palmitoyltransferase II (CPT II), very
long-chain acyl-CoA dehydrogenase (VLCAD), and CYP2D6.
The conclusion was that there was no obvious relationship
between the genetic mutations observed in this study and rhab-
domyolysis (Matsusue et al., 2011).
Neuropsychological alterations seen in many metham-
phetamine users are often unrelated to its lifetime consumption
or length of abstinence. In a series of 52 methamphetamine
users the contribution of CYP2D6 polymorphism to variability
observed in long-term effects was studied. EM subjects showed
worse overall neuropsychological performance and were three
times as likely to be cognitively impaired as IMs/PMs. Apparently,
a more efficient metabolic disposition of methamphetamine is
associated with a poorer cognitive performance. It has also
been suggested that metabolism may generate metabolic species
involved in the underlying mechanism of neurotoxicity (Cherner
et al., 2010).
METHAMPHETAMINE DRUG—DRUG INTERACTION
The administration of inhibitors of CYP2D6 activity can influ-
ence the metabolism of methamphetamine, and metham-
phetamine can inhibit the metabolism of CYP2D6 substrates. The
number of published drug-interaction studies with this class of
substances is very scarce. Previous administration of bupropion,
a known CYP2D6 inhibitor, produces a large increase of metham-
phetamine concentrations, and a reduction in amphetamine
ones. The pharmacological effects of methamphetamine (cardio-
vascular and euphoria-like ones) were decreased by bupropion
(Newton et al., 2005, 2006).
Antiretroviral drugs (ritonavir, a known CYP2D6 inhibitor)
have been reported to be the main cause of life-threatening
interactions with methamphetamine (Hales et al., 2000).
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CONCLUDING REMARKS
The involvement of CYP2D6 polymorphism in the metabolic
clearance of both MDMA and methamphetamine leads to the
speculation that it should have an impact on acute and long-term
drug toxicity and drug taking behavior.
Concerning acute effects, those subject carriers of alleles with
a reduced functionality are at higher risk, for both MDMA and
methamphetamine, of experiencing heightened pharmacologi-
cal effects. Moreover, in combination with some environmental
factors this may lead to acute toxicity episodes including death.
Irrespective of the initial dose, the following one results in the
MBI of MDMA and phenocopying to the PM phenotype thus
diluting the variability incorporated by the genetic polymorphism
and, consequently, putting all subjects at risk of acute effects. With
respect to methamphetamine, because a large portion of drug
users are of Asian origin, and carriers of the lower functionality
allele *10, most of these subjects should also experience increased
effects.
Concerning the relevance of CYP2D6 polymorphism on drug
abuse, preliminary data from methamphetamine suggest that
an increased CYP2D6 functionality may lead to an increased
abuse of the substance. An observation that is more rele-
vant for methamphetamine, with a higher abuse liability, than
MDMA.
Regarding neurotoxicity, only in the case of MDMA may
a metabolic bioactivation be involved in long-term neurotoxic
effects. Theoretically those subject carriers of CYP2D6 func-
tional alleles (including those carriers of duplications) and with
a low COMT activity should be the most efficient in generating
metabolic neurotoxic species and, consequently, the most vulner-
able to neurotoxicity. Again the MBI of MDMA should be taken
into consideration after repeated doses.
Metabolic clearance of both methamphetamine and MDMA
ranges from 50% to 75%, there is, therefore, a relevant contri-
bution of renal excretion in plasma clearance. The fraction of
metabolic clearance regulated by CYP2D6 is lower than 50%
for both drugs and other isozymes of cytochrome P450 con-
tribute to their clearance. Both factors combine with catalytic
activities, and MBI behavior in case of MDMA, to tune down
the potential contribution of CYP2D6 polymorphism in clinical
outcomes of both substances. Although MDMA and metham-
phetamine are the most consumed ATS many substances of this
group are substrates of CYP2D6. Thus, in possible future reports
on other substances it would not be surprising to find that the
CYP2D6 polymorphism has a strong role in the clinical outcome
of drug users. The difficulty in performing controlled clinical
studies with drug users stratified as a function of drug metab-
olizing polymorphisms, limits the evaluation of their clinical
impact.
In summary, the genetic polymorphism of CYP2D6 and co-
administration of CYP2D6 inhibitorsmay have less impact on the
risk of acute toxicity than previously thought, whereas the role of
metabolism by other cytochrome P450 enzymes and renal excre-
tion assumes greater importance with regard to systemic exposure
to unchanged drug. Globally, the clinical relevance of CYP2D6
polymorphism is lower than that predicted by in vitro studies.
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